1. Home
  2. IMMR vs PLX Comparison

IMMR vs PLX Comparison

Compare IMMR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$6.12

Market Cap

216.7M

Sector

Technology

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.12

Market Cap

230.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
PLX
Founded
1993
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
216.7M
230.0M
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
IMMR
PLX
Price
$6.12
$2.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$13.50
$12.00
AVG Volume (30 Days)
308.9K
1.0M
Earning Date
02-27-2026
03-18-2026
Dividend Yield
4.83%
N/A
EPS Growth
82.69
N/A
EPS
N/A
N/A
Revenue
$35,013,000.00
$52,744,000.00
Revenue This Year
N/A
$37.52
Revenue Next Year
N/A
$1.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.65
$1.34
52 Week High
$8.15
$3.19

Technical Indicators

Market Signals
Indicator
IMMR
PLX
Relative Strength Index (RSI) 47.79 33.67
Support Level $5.77 $2.03
Resistance Level $6.39 $2.14
Average True Range (ATR) 0.19 0.11
MACD 0.00 -0.09
Stochastic Oscillator 43.55 8.42

Price Performance

Historical Comparison
IMMR
PLX

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: